Company intelligence / Profile preview
VeonGen Therapeutics
Munich, Germanyveongen.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
VeonGen’s lead program VG801 is in a first-in-human Phase 1/2 clinical trial for Stargardt disease and has received FDA Rare Pediatric Disease Designation as well as acceptance into the FDA’s Rare Disease Endpoint Advancement pilot program. The company also has a second clinical-stage program, VG901 for retinitis pigmentosa caused by CNGA1 mutations. Both programs are enabled by proprietary gene delivery platforms designed to overcome limitations of current AAV-based therapies[1][5][6].
- Therapeutic areas
- Ophthalmology
- Modalities
- Gene therapyAdeno-associated virus (AAV)-based gene therapyDual AAV gene therapy
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Exploring partnerships with biopharmaceutical companies in other therapeutic areas beyond ophthalmology[2]. No specific partners named.
Beyond the preview
Go deeper on VeonGen Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VeonGen Therapeutics.